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Abstract.  This study describes the identification of 
seven amino acid residues of the vascular cell adhe- 
sion molecule (VCAM-1) that influence binding to the 
ot4/31 receptor. Using recombinant murine VCAM-1- 
IgG, which is bound by both mouse (WEHI 231) and 
human (Ramos) lymphoid cells, two approaches 
demonstrated the crucial role of the first two NH2- 
terminal Ig-like domains in binding: (a) blocking 
monoclonal anti-mouse VCAM-I antibodies bound to 
only truncation variants that included the first two do- 
mains; (b)  site-direct mutagenesis of the first NH2- 
terminal domain showed that alanine substitution of 
the amino acid residues R36,  D40, K46,  $54, N65, 
T72, and E81  partially or completely reduced adher- 
ence by human and/or mouse cells. Of these D40, 
when mutated to A, N, or K (but not E), showed 
complete abrogation of adherence by mouse and hu- 
man cells, as well as inability to bind blocking anti- 
murine VCAM-1 antibody MVCAM.A429, while not 
inducing gross structural perturbations in VCAM-1. By 
molecular modeling, the 1340 residue was located on a 
/3 turn connecting two/3 strands defined as C and D. 
The residues R36,  K46,  $54, N65, T72, and ES1, 
which perturb cell adherence and caused small 
changes to gross structure, are conformationally near 
or adjacent to D40.  Although these residues, identified 
as crucial for cell adhesion, are all located in domain 
1, it is evident that there is a structural requirement 
for domains 1 and 2 to be intact so that cell adhesive 
function can occur. 
T 
n~  vascular  cell  adhesion  molecule-1  (VCAM-1)  1 
plays a major role in the adhesion of leukocytes to in- 
flamed microvascular endothelium (6, 27, 37, 45), be- 
ing one of a few molecules that are induced by proinflamma- 
tory cytokines such as IL-1, TNF-¢, or IFN-,y. It is involved 
with intercellular adhesion moleculeq and endothelial-leu- 
kocyte adhesion moleculeq in the transmigration and local- 
ization of lymphocytes, monocytes, eosinophils,  and baso- 
phils (but not neutrophils) to sites of tissue inflammation (7, 
19, 26, 44). Its interaction with these types of leukocytes ap- 
pears to be via very late antigen-4 (VLA-4, t~4/51), a/31 inte- 
grin molecule found on all four, but not on neutrophils (12). 
It also has been shown to interact with ot4/37 (ot4/3P), the 
lymphocyte  Peyer's patch homing receptor (8, 40). VCAM-1 
expression has been detected not only on cytokine-activated 
endothelium, but also on bone marrow stromal cells (22, 23, 
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41), myoblasts (39), lymphoid dendritic cells and tissue mac- 
rophages (38), rheumatoid synovium (20, 35, 47), cytokine- 
stimulated neural cells (4), parietal epithelial cells in Bow- 
man's capsule, and renal tubular epithelium associated with 
nephritis  (43, 52).  It has been detected at various  sites of 
inflammation  associated  with cardiac and renal allograft 
transplant  rejection (5, 14, 29) and with acute graft versus 
host disease of the large intestine (25). Treatment of experi- 
mental animals with monoclonal antibodies to VCAM-1 has 
delayed murine cardiac allograft rejection (29, 30).  Anti- 
o~4 and/or anti-VCAM-1 monoclonal antibodies  have been 
shown to block migration of lymphocytes, monocytes, and 
eosinophils into tissue, and to exhibit anti-inflammatory ef- 
fects in animal models of experimental allergic encephalo- 
myelitis, contact hypersensitivity  reactions, and passive cu- 
taneous anaphylaxis  (1,  13,  18, 50, 53). 
Structurally, VCAM-1 has been described as a member of 
the immunoglobulin superfamily. It is expressed on cytokine- 
activated endothelium as either a 110,000-mol wt transmem- 
brane glycoprotein with seven Ig-like extracellular domains, 
or as alternatively spliced six or eight Ig-like domain forms 
(9,  16, 27, 32,  33, 37).  The predominant form in the hu- 
man, mouse, rat, and rabbit is reported to be the seven- 
domain form (9,  16, 32, 33).  More recently, VCAM-1 has 
been seen expressed as a truncated 40,000-mol wt phospha- 
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ney tissues (24). 
There have been recent reports that molecules comprising 
only the NH2-terminal domains 1-3 were sufficient for both 
adhesion and costimulatory activation of T lymphocytes (10, 
31).  Two studies  reported that the first NI-Ix-terminal  do- 
main and the homologous domain 4 were involved in binding 
to VLA-4 (28,  48).  In the work presented here, we inves- 
tigate the binding of a panel of secreted recombinant DNA- 
derived, murine VCAM-1 molecules to murine and human 
c~4B1 to elucidate the  structure/function relationships  for 
adhesion. We will show that a cluster of amino acids in do- 
main 1 of VCAM-1 are crucial for binding to the c~4~1 recep- 
tor of mouse WEHI 231  and human Ramos cells. 
Materials and Methods 
Cloning and Expression of  Murine VCAM-I 
A  mouse peripheral lymph node eDNA library was constructed using a 
eDNA library kit (lambda gtl0; Invitrogen, San Diego, CA) and poly(A)  + 
RNA  isolated from murine TNF-c~-stimulated mouse peripheral lymph 
nodes. The probe used to screen a library of ,~1 million lambda gtl0 bac- 
teriophage was a  random-primed (Boefiringer Mannheim Biochemicals, 
Indianapolis, IN) full-length eDNA encoding human VCAM-1  (gift of D. 
Dowbenko, Genentech Inc., South San Francisco, CA). Hybridizing clones 
were subcloned into pBluescript (Stratagene, La Jolla, CA) and sequenced 
using the Sequenase Version 2.0 kit  (United States Biochemical Corp., 
Cleveland, OH). A full-length eDNA was identified and entirely sequenced. 
The sequence for our murine VCAM-1 was identical to that reported by Hes- 
sion et al. (17). 
The eDNA for murine VCAM-1 was truncated to remove the nucleotides 
encoding both the transmembrane domain and  the cytoplasmic tail  (at 
amino acid residue N667) using the following primers: 
Primer 1: 5'-GGAAGAATTCGCGGCCCJCTTCACGTGGC~-Y 
Primer 2: 5'-GGAAGTCGACCTAATGTTCTTTTCCTTTTA-Y 
The 2.2-kb EcoRI-Sall PCR product was subcloned into pRK5 and ex- 
pressed in human 293 embryonic kidney cells as previously reported (2). 
The  resulting  truncated  murine  VCAM-1  molecule  was  designated  as 
MVdl-7. A 2.2-kb EcoRI-EcoRV PCR product was ligated to an EcoRV-SalI 
fragment encoding the hinge, CH2, and CH3 regions of murine IgG1. The 
resulting EcoRI-SalI fragment containing the murine VCAM-I-IgG chimera 
(designated MVIdl-7) was subcloned into a eucaryotic expression vector 
pRK5 and expressed in human 293 cells. 
Purification of these proteins proceeded as follows: Scram-free condi- 
tioned medium from 293 cells expressing MVdl-7 was purified by affinity 
chromatography on rabbit antimurine MVdl-7-Sepharose (Pharmacia LKB 
Biotechnology Inc.,  Piscataway,  NJ).  MVIdl-7 was passed over protein 
A-Sepharose (Pharmacia, Uppsala, Sweden). Both types of  molecules were 
eluted with 100 mM acetic acid, 500 mM sodium chloride, pH 3.0. The 
eluents were dripped into one-tenth volume of 1 M Tris (pH 7.5) to neutral- 
ize the samples. The samples were then dialyzed against phosphate-buffered 
saline, and concentrated using a pressurized stir cell (Amicon Corp., Dan- 
vers, MA.). The proteins were run on 7% SDS-PAGE to assess purity.  The 
MVdl-7 was a monomer of 110 kD under both nonreducing and reducing 
conditions. The MVIdl-7 was a dimer of  230,000 mol wt under nonreducing 
conditions and a monomer of 115,000 tool wt under reducing conditions. 
Truncated Variants of  Murine VCAM-I-IgG Chimera 
MVIdl-7 is composed of seven Ig-like domains. Experiments were carried 
out with domain truncation variants. Each domain of MVIdl-7 was sequen- 
tially truncated, starting at the COOH terminus (domain 7), to evaluate the 
binding function of each truncation variant. Domains in the murine mole- 
cule were defined as regions homologous to the human molecule according 
to Osborn et al. (27):  domain 1 comprised amino acid residues F1 to I84; 
domain 2, H85 to L193; domain 3, Q194 to E286; domain 4, K287 to $378; 
domain 5, F379 to Y482;  domain 6, V483 to V574;  and domain 7, $575 
to H666.  Primers were synthesized to truncate the full-length eDNA by 
PCR (Perkin-Elmer Cetus Instruments, Norwalk, CT) before amino acid 
positions H85, Q194, K287, F379, V483, and $575. Each primer introduced 
restriction endonuclease sites as well as a stop codon to facilitate subcloning 
and expression. To aid in the purification of the truncated VCAMs, further 
constructs were made in which the cDNA encoding the hinge, CH2, and 
CH3 of murine IgG1 were ligated to each of the truncated cDNAs to gener- 
ate Ig chimeras.  They were designated as MVIdl,  MVIdl-2,  MVIdl-3, 
MVIdl-4, MVIdl-5, and MVIdl-6, respectively, with the wild type (WT) 
as MVIdl-7. 
Site-directed Mutagenesis of VCAM-I-IgG Chimera 
Mutations were introduced into the cDNAs encoding MVIdl-4 and MVIdl-7 
by the method of Kunkel et al. (21) (Muta-Gene Phagmid In Vitro Mutagen- 
esis Kit; Bio-Rad Laboratories, Richmond, CA) according to the manufac- 
turer's instructions. Plasmids positive for the introduced mutations were 
confirmed by sequencing and expressed transiently in 293 cells. The con- 
centration of each mutant in serum-free conditioned medium was quantified 
by ELISA using a goat anti-mouse IgG1 antibody as previously described 
(49). Mutation sites were defined using the following nomenclature: IMOA 
describes aspartic acid mutated to an alanine at position 40. 
Antibodies 
HP2/1  (rat anti-human a4 chain) was purchased from Amac, Inc. (West- 
brook, ME). It has been previously described and reported to bind human 
a4 and block lymphocyte binding to haman VCAM-1 and fibronectin (36, 
42). PS/2 (rat anti-mouse a4 chain-specific antibody) was obtained from 
the American Type Culture Collection (Rockville, MD). It has been previ- 
ously reported to recognize the a4 chain of murine VLA-4 (22).  Rabbit 
anti-mouse VCAM-1 (anti-mVCAM-1)  antiserum was prepared by immuni- 
zation of rabbits with recombinant derived MVIdl-7 in Freund's adjuvant. 
It was purified on protein A and immunoaffinity depleted of anti-mouse IgG 
activity on Sepharose-conjugated mouse IgG (Pharmacia LKB Biotechnoi- 
ogy Inc.).  The preparation was 0.28  mg/ml with and endpoint titer of 
>1:25,600 for anti-MVdl-7 and 1:158 for anti-mouse IgG by ELISA analy- 
sis.  A  concentration of 10  #g/mi was used in blocking experiments. It 
specifically blocked adhesion of WEHI  231  to 24-h TNF-c~-stimulated 
mouse hemangioendothelioma cells, but had no effect on blocking Ramos 
cells binding to TNF-a-stimnlated human umbilical cord vein endothelial 
cells (Cell Systems Corp., Kirkland, WA). 
Armenian hamsters  were immunized intraperitoneally with 5  #g  of 
recombinant  MVIdl-7-emulsified in  monophosphoryl lipid  A/trehalose 
dimycolate adjuvant (Ribi ImmunoChem Research, Inc., Hamilton, MT). 
3  d  later,  the  spleens  from  the  immunized  animals  were  fused  with 
P3x63Ag801  myeloma  cells  using  polyethylene  glycol.  Positive  anti- 
mVCAM-1 hybridomas were screened by ELISA for binding to soluble 
MVdl-7.  Seven monoclonal antibodies were selected and characterized. 
These were designated 5.7.1, 5.7.4, 5.10.8, 5.11.3, 35.1.1, 59.9.4,  and 59.17.19. 
Clones 59.9.4  and 59.17.19 are cell adhesion-blocking monoclonal anti- 
bodies as determined by blocking of WEHI 231 or Ramos cell binding to 
MVdl-7.  All seven monoclonal hamster anti-mVCAM-1 antibodies recog- 
nized purified recombinant MVdl-7 as a single band of ,,ol 10 kD by Western 
blot/SDS-PAGE under reducing conditions and by immunoprecipitation of 
cell extracts of murine Bend3 cells (a gift from Susan Watson, C~nentech, 
Inc.). A hamster IgG (PharMingen, San Diego, CA) was used as a control 
immunoglobulin. 
The hamster anti-mVCAM-I antibodies were used to assess structural al- 
terations in the MVIdl-4 and MVIdl-7 site-directed mutants. The 293 cell 
transfectant supernatants (100 #1) from the mutants were added to coats of 
0.2 #g/ml goat anti-mouse IgG (Cbemicon International Inc., Tecmecula, 
CA) on microtest wells (NUNC-Immuno Plate, MaxiSorp; Alameda Chem. 
& Sci., Inc., Oakland, CA) that had been blocked with 10 mg/ml of BSA 
in phosphate-buffered saline for 2 h at room temperature. An equivalent 
amount of mutant and MVIdl-4 or MVIdl-7 (WT) protein were incubated 
for  1  h  at  room  temperature.  100  #1  of  each  monoclonal  hamster 
anti-mVCAM-1 antibody solution was added, and the microtest wells were 
again incubated for 1 h at room temperature. The bound hamster antibodies 
were detected by a 1-h incubation with goat anti-hamster IgG labeled with 
alkaline phosphatase at 1:2,000  dilution (Caltag Laboratories, South San 
Francisco, CA). The enzyme activity was detected with 1 mg/ml ofp-nitro- 
phenyl phosphate, disodium (Sigma Chemical Co.,  St.  Louis, MO),  in 
50 mM carbonate, 10 mM MgCI2 for 30 rain at room temperature. The op- 
tical density at 405 nm was recorded on a microplate reader (Molecular 
Devices Corp., Menlo Park,  CA). 
Two  blocking  rat  anti-mVCAM-1  antibodies  were  used  for  binding 
studies and for the assessment of changes to gross structure. The M/K-2.7 
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scribed as a blocking antibody for the binding of human lymphoma cells 
to mouse endothelial ceils (23). MVCAM.A429 was obtained from Phar- 
Mingen. 
Cell Adhesion Assay 
Recombinant MVdl-7 and MVIdl-7 were precoated onto separate microtest 
wells (NUNC-Immuno Plate, MaxiSorp) at 1 ~g in 100/zl/well for 1 h at 
room temperature. The wells were quenched with RPMI 1640 containing 
5 mg/mi BSA. The test cells were labeled with 2',7'-bis-(2-carboxyethyl)- 
5(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF) from Molecu- 
lar Probes (Eugene, OR) for 30 rain at 37°C according to the method of 
Gimbrone et al. (15). The labeled cells were suspended at 4  x  106 cells/mi 
in RPMI 1640 containing 5 mg/mi BSA. Test cells were incubated with im- 
mobilized MVdl-7, or MVIdl-7, at 37"C for 15 min. The nonadherent cells 
were removed by centrifugation of  the sealed microtest plate in the inverted 
position at 200 g for 5 min. The supernatant was aspirated. The bound ceils 
were solubilized with 0.1% SDS in 50 mM Tris/HCl, pH 8.5. The propor- 
tion of  adherent ceils was determined for each well by measuring the amount 
of released fluorochrome from lysed cells on an analyzer (Fluorescence 
Concentration Analyzer; Pandex, Mnndelein, IL) set at 485-nm excitation 
and 535-nm emission wavelengths. Adherence was also performed on mi- 
crowells precoated with human fibronectin (Sigma Chemical Co.). 
For the test of MVIdl-4 and MVIdl-7 site-directed mutants in the adhe- 
sion assay, serum-free culture  suporuatants from 293 cell transfectants were 
serially added to microwells that had been coated with 200 w/well goat 
anti-mouse IgG1 (Caltag Laboratories) and quenched with 5 mg/ml BSA. 
Supernatants were incubated for 2 h at room temperature. For the assess- 
ment of the amount of each mutant protein captured on the microwells, an 
alkaline phosphatase-labeled goat anti-mouse IgG1 (Caltag Laboratories) 
at hl,000 dilution was added, and wells were incubated for 1 h at room tem- 
perature. The enzyme activity was detected with p-nitrophenyl phosphate 
disodium, taking optical density readings at 405 nm. The sensitivity of this 
capture assay was such that protein concentration determinations and cell 
binding analysis of mutants could be made within the concentration range 
of 20-150 w/ml. 
The cell adhesion assay described above was repeated with the following 
variation for both MVIdl-4 and MVIdl-7. For the assessment of Ramos cell 
binding to mutant MVI, BCECF-labeled cells were added as above. FOr 
WEHI 231  cell binding, a rat anti-mouse Fe3,RII antibody (PharMingen) 
at 2 t~g/10  ~ cells was added to block binding through the Fc receptor (46). 
To block the binding of WEH1231 cells through the cell-surface IgG to the 
goat anti-mouse IgGl precoat, 2 t~g/ml of mouse IgG1 (Calbiochem, San 
Diego, CA) was added to the assay medium. 
Model of  Murine VCAM-1 Domain 1 
A model of MVdl was based on the crystal structure of a human IgG CH1 
domain (11). Alignment of the MVdl sequence with CH1 (Fig. 1) was per- 
formed manually using C23, C71, W35, $54, and the requirement for hydro- 
phobic residues at buried positions to guide the alignment. In human CH1, 
the W35 sidechain forms a hydrogen bond with the $54 sidechain; this was 
retained in the MVdl model. Insertions and deletions in MVdl relative to 
human CH1  occur in the loops connecting the/~ strands. In addition, /~ 
strands D  and E  are shorter in MVdl (Fig.  1). 
CHI was transformed into MVdl in two steps. First, all residues except 
those involving insertions or deletions were changed to the MVdl sequence 
using the INSIGHT-II program (Biosym Technologies, San Diego, CA). 
Where possible, conformations of MVdl sidechains were kept similar to 
those of CHI; otherwise, they were based on rotamer libraries (34), pack- 
ing, and hydrogen bonding considerations. Second, loop structures contain- 
ing the MVdl insertions or deletions were gleaned from searches of the Pro- 
tein  Data  Bank  (3)  crystal  structures using  the  INSIGHT-I/  program. 
Several loop conformations were possible for each new loop, and in each 
case, the choice was based on the nature of  the MVdl amino acids. The loop 
connecting/~ strands C and D (loop CD) is relatively large (10 residues) 
and several loop conformations were evaluated. 
The MVdl model was subjected to energy minimization using the DIS- 
COVER program (Biosym Technologies). The all-atom AMBER foreefield 
(51) was used for all calculations, using a 14-/~ cutoff for nonbonded inter- 
actions and a linear dielectric (¢ =  4.0*0. Before minimization, hydrogen 
atoms were added to the structure using INSIGHT-H,  and positions of 
hydrogens on  serine,  threonine,  and  tyrosine  sidechains were  checked 
visually for proper alignment in hydrogen bonds, if present. Energy minimi- 
~-strand  A  ~-strand  B  ~-strand  C 
•  .#.#  •  .#.#.#.#  .... 
humCHl  KGPSVF  PLAPS  SKSTSGGT -AALGCLVKDYF PEPVTVSWNSGALT 
muVCAM-DI  FKI  E  I  S  PEYKTIAQIGDSMALTC  STTGC  E  S-  -  PLFSWRTQI  DS 
ratVCAM-DI  FKI  EI  S  PEYKTLAQIGDSMLLTCSTTGCES--  PSFSWRTQIDS 
huVCAM-DI  FKIETTPESRYLAQIGDSVSLTC  STTGCES-- PFFSWRTQIDS 
1  l0  20  30  40 
humCHl 
muVCAM-I 
ratVCAM-I 
huVCAM-I 
~-strand  D  ~-strand  E  ~-strand  F 
*#*#*#  .#.#.#.# ...... 
SG--yHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ-TYICNVNH 
PLNAKVRTEGS .........  KSVLTMEPVSFENEHSyLCTATC 
PLNGKVKTEGA .........  KSVLTMDPVSFENEHSYLCTATC 
PLNGKVTNEGT .........  TSTLTMNPVSFGNEHSYLCTATC 
50  60  70 
~-strand  G 
humCHl  KPSNTKVDKKVEPKSC 
muVCAM- 1  GS--GKLER$IHVDIY 
ratVCAM-I  NS--GKLERGIQVDIY 
huVCAM- 1  ES-  -RKLEKGIQVEIY 
8O 
Figure 1. Alignment of human, rat, and murine VCAM-dl with hu- 
man IgG CH1. B strands in human IgG CH1 crystal structure and 
mVCAM-dl model are underlined. Residues in the human IgG CH1 
crystal structure are denoted as buried (o), partially buried (*), or 
at the CH1-CL interface (#). 
zation was performed in three stages. In stage one, 500 cycles of steepest- 
descents  minimization  were  used.  46  hydrogen  bond  constraints  (50 
kcal/mol)  were  also  invoked:  37  mainchain-mainchain,  8  mainchain- 
sidechain, and  1 sidechain-sidechain hydrogen bonds. This allowed new 
loop structures and all sidechains to move while preserving the integrity of 
the  CHI  protein fold.  In  stage two  (1,000  cycles),  conjugate-gradient 
minimization was used. In stage three (5,690  cycles), the hydrogen bond 
constraints were released, and the minimization continued until the maxi- 
mum derivative was <0.01  kcal/mol-/~. 
Results 
Cell Binding to Immobilized 
Recombinant Murine VCAM-1 (MVdl-7) and Murine 
VCAM-I-IgG (MVIdl-7) 
Two secreted,  soluble,  and recombinant  forms of murine 
VCAM-1 exhibited binding specificity  to ot4/31-positive lym- 
phoid cells. BCECF-labeled  murine WEHI 231 and human 
Ramos cells bound to both MVdl-7 and MVIdl-7 above the 
basal level binding that they exhibited with BSA (Fig. 2, A 
and C). The binding of the murine and human cells was in- 
hibited  by  PS/2  (anti-murine  ol4  subunit  antibody)  and 
HP2/1 (anti-human oL4), respectively,  but not by a rat IgG2b 
isotype control antibody (Fig. 2, B and D). A rabbit antimu- 
rine VCAM-I antiserum also inhibited binding. This binding 
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Figure 2. Binding of BCECF- 
labeled  murine  WEHI  231 
and human Ramos ceils to mi- 
crowells preeoated with vary- 
ing concentrations of recom- 
binant soluble MVdl-7 (e) and 
MVldl-7 (o). Binding is ex- 
pressed as fluorescence units 
+ SD. (A) WEH1231 and (C) 
Ramos.  (B)  The binding of 
WEHI 231 to MVIdl-7 is in- 
hibited by anti-~4 antibodies 
PS/2 (10/~g/ml). (D) The bind- 
ing of Rarnos to MVIdl-7 (n) 
is inhibited by HP2/1 (10/~g/ 
ml).  K562,  ~4-negative cell 
(m). The peak binding fluores- 
cence for WEHI 231  repre- 
sents an average of 76  +  4 % 
(SD) of the input cell number 
(2  x  105  cells/well).  The 
peak binding by Ramos cells 
represents 38 :[: 13% (SD) of 
input number of cells. 
is therefore ot431/VCAM-1 dependent. This same pattern of 
binding,  with  inhibition by anti-VCAM-1  antiserum,  was 
seen when rat splenocytes and rabbit peripheral lymphoid 
cells were the source of ct4 (data not shown). We have seen 
similar binding by human ot4-positive  Jurkat T cells (data not 
shown). The ot4-negative control cell line K562 did not bind 
to precoated MVIdl-7. The Ramos and K562 cells bear sur- 
face Fc~RII receptors, therefore, the binding of the MVIdl-7 
is not caused by interaction via the Fc domain of the fusion 
protein. 
These data showed that the recombinant soluble molecules 
MVdl-7 and MVIdl-7 were functionally active,  similar in 
their interaction with the homologous mouse VLA-4 recep- 
tor, and cross-reactive with VLA-4 from several other differ- 
ent animal species, including humans. 
Binding of Cells and Anti-VCAM-1 Monoclonal 
Antibodies to Truncated Variants of  MVIdl-7 
The  first  two  NH2-terminal  Ig-like  domains  on  murine 
VCAM-1 were both necessary and sufficient for binding to 
murine WEH1231 and human Ramos cells. Domain deletion 
mutants, expressed as chimeric IgG molecules in serum-free 
conditioned media,  were captured on separate microwells 
precoated with goat anti-mouse IgG antibody and presented 
to cells at 0.23 nM. This concentration had previously been 
determined to be saturating for all variants by an immunoas- 
say under the antibody capturing condition. As illustrated in 
Fig. 3, A and B, variant chimeric fusion molecules composed 
of the  first two or more of the  seven Ig-like domains  of 
VCAM-1 were sufficient to bind both WEHI 231 and Ramos 
cells. The variant MVIdl, composed of only the first domain 
of VCAM-1 fused to the hinge, CH2, and CH3 domains of 
IgG heavy chain, was not capable of binding cells, even at 
a molar concentration 30-fold higher than the other mutants. 
MVIdl was inactive. The supernatant fluids from the back- 
ground control pRK5 mock transfectant 293 cells added to 
the goat anti-mouse IgG precoat did not exhibit cell binding. 
The binding by Ramos cells to the MVI variants could be 
inhibited  totally  by  monoclonal  hamster  anti-mVCAM-1 
(clone 59.17.19), but not by normal hamster IgG (Fig. 3 C). 
Inhibition was also observed for another monoclonal ham- 
ster anti-mVCAM-1  (clone 59.9.4)  and two commercially 
available  blocking  rat  anti-mVCAM-1  antibodies  tested, 
M/K-2.7 (23) and MVCAM.A429.  No blocking of cell ad- 
herence was observed for five other hamster anti-VCAM-1 
monoclonal  antibodies  tested  (clones  5.7.1, 5.7.4,  5.10.8, 
5.11.3, and 35.1.1; data not shown). The cell binding was in- 
hibited by PS/2 for mouse cells and HP2/1 for human cells, 
but not by equivalent concentrations of a rat IgG2b or mouse 
IgG1 control antibody respectively (data not shown). These 
data  suggest  that  the  NH2-terminal  domains  1-2  of the 
recombinant murine VCAM-I-IgG are sufficient for binding 
to either WEHI 231  or Ramos cells. 
In corroboration, blocking monoclonal antibodies (59.9.4, 
59.17.19,  M/K-2.7,  and MVCAM.A429)  were observed to 
bind to truncated routine VCAM-I-IgG molecules bearing, 
at minimum,  the first two NH2-terminal Ig-like domains, 
MVIdl-2 to MVIdl-7 (Table I). Nonblocking monoclonal an- 
tibodies bound  to MVIdl-3  through  MVIdl-7,  but not to 
MVIcI1-2. None of the antibodies tested bound to MVIdl. 
These  results  support  the  hypothesis  that  the  structures 
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Figure 3.  Cell binding to truncated versions of murine VCAM- 
1-IgG derived  from 293  cell  transfection  culture  supernatants. 
VCAM-I-IgG variants  were captured at '~0.23 nM on microwei1 
procoats of goat anti-mouse IgG (1/zg/ml). PRK5 CTRL denotes 
a  293  cell mock transfection supernatant.  Binding  is  expressed 
as  fluorescence units  +  SD.  (A)  WEHI 231,  (B)  Ramos,  and 
(C)  Ramos  cell  binding  is  blocked  by  10  ttg/well  of hamster 
anti-mVCAM-1  antibody ([]), but not by  10/~g/well of hamster 
IgG (v~). 
Table II. MVIdI-4 Mutant Binding Summary 
Binding to cells 
~4B1  a4#l  Transfectant 
WEHI 231"  Ramos*  expression* 
WT (MVIdl-4)  +  +  + 
293  Mock control  -  -  - 
Domain 1 
E8A  +  +  + 
K10A  +  +  + 
D17A  +  +  + 
E29A  ND  -  - 
$34A  ND  +  + 
R36A  -  -  + 
T37A  +  +  + 
Q38A  ND  -  - 
IMOA  -  -  + 
D40K  -  -  + 
N44A  +  +  + 
K46A  +  +  + 
R48A  +  +  + 
E50A  +  +  + 
$54A  -  -  + 
T57A  +  +  + 
E59A  +  +  + 
E64A  +  +  + 
N65A  +  -  + 
E66A  +  +  + 
H67A  ND  -  - 
L70A  ND  -  - 
T72A  +  -  + 
K79A  +  +  + 
ES1A  +  -  + 
R82A  +  +  + 
H85A  +  +  + 
* Cell binding key:  +,  >80%  of WT;  5:,  <50%  of WT;  -,  <10%  no 
binding; ND, not done.  ~: Determined by anti-IgG ELISA: +, expression; -, 
no expression. 
sufficient  for  adherence  reside  within  the  first  two  NH2- 
terminal domains. 
Specific Amino Acid Residues on 
Domain I of MVIdl-4 and MVIdl-7 Are Required 
for Cell Binding 
A  series  of  soluble  MVIdl-4  mutants  with  L-alanine  or 
L-lysine substitutions in domain 1 residues was expressed in 
293 cells to test whether the first domain alone was sufficient 
Table I.  The Binding of Monoclonal Hamster and Rat Anti-Murine VCAM-1 to Truncated VCAM-I  lgG 
OD at 405 nm 
mAb  293  MVIdl  MVIdl-2  MVIdl-3  MVIdl-4  MVIdl-5  MVIdl-6  MVIdl-7 
5.7.1  0.199  0.226  0.159  0.53  0.596  0.605  0.647  0.634 
5.7.4  0.301  0.278  0.241  0.657  0.669  0.693  0.748  0.631 
5.10.8  0.197  0.213  0.175  0.59  0.593  0.594  0.685  0.437 
5.11.3  0.246  0.232  0.213  0.575  0.596  0.585  0.624  0.526 
35.1.1  0.152  0.151  0.144  0.451  0.444  0.453  0.48  0.438 
59.9.4  0.162  0.154  0.668  0.72  0.747  0.743  0.711  0.583 
59.17.19  0.334  0.296  0.643  0.63  0.632  0.696  0.653  0.502 
M/K-2.7  0.044  0.071  0.357  0.339  0.315  0.345  0.365  0.452 
MVCAM.A429  0.017  0.036  0.835  0.854  0.872  0.901  0.904  0.977 
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Figure 4.  Alanine substitutions at specific amino acid residues in 
domain I of MVIdl-4 that affected Ramos cell binding are illus- 
trated. MVIdl-4 mutant supernatants derived from 293 cell trans- 
fections were serially diluted and added to microwells coated with 
goat anti-mouse  IgG. Equivalent concentrations of mutants and 
MVIdl-4 (WT) were used in the adherence assay as shown by rela- 
tive OD405 values determined for serial dilutions of mutants and 
WT captured on the anti-IgG-coated microwell (illustrated in the 
top panels of A-J). The R36A and D40A mutant supernatants con- 
tained '~160 ng/ml (1:4) of anti-IgG-reactive protein as compared 
to MVIdl-4. The K46A mutant contained 160 ng/ml (neat). $54A 
contained '~40 ng/ml. The N65A mutant contained 300 ng/ml (1:2 
dilution) and the ESIA mutant contained 640 ng/ml at 1:2 dilution). 
The T72A mutant and the K10A mutant were at 160 ng/ml each at 
1:2  dilution. The  binding of  BCECF-Iabeled Ramos  cells  is 
recorded as relative fluorescence +SD (bottom panels of  A-F, I and 
J), The binding of WEH1231 is similarly reported (bottom panels 
of G and H). The binding is compared  to the negative control PRK5 
mock transfecdon 293 cell culture supernatant or as in B, to the mu- 
tation Q326A. 
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for adhesive function.  The mutants are listed and the cell 
binding data is summarized in Table II.  The concentrations 
of mutant MVIdl-4 molecules tested ranged from 40 to 640 
ng/ml, as determined by comparison to a purified MVIdl-4 
standard.  A  mock pRK5  vector  transfectant  supematant 
from human 293 cells was used as a background control. 
Ramos and WEH1231 cells exhibited no binding to D40A, 
D40K,  and $54A mutants as compared to equivalent con- 
centrations of the wild type MVIdl-4 molecule or to mutant 
Q326A. Representative binding curves for D40A and $54A 
are shown in Fig. 4, B and D, respectively. The lack of bind- 
ing by Ramos cells to the D40K mutant was identical to that 
observed for D40A (data not shown). Based on a computer- 
generated model of domain 1 (Fig. 5), the D40 residue is as- 
sociated with a/~ turn between ~ strands C and D. Mutation 
of this  hydrophilic residue  should not greatly perturb  the 
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model of the first domain of mu- 
rine  VCAM-1.  /3  strands  are 
shown as beige-colored ribbons; 
~-helix (loop EF and part of loop 
AB) is in purple,  Relevant side- 
chains tested  for their effect on 
binding  are colored  as  follows: 
blue,  no  effect;  green,  partial 
reduction;  yellow, complete  re- 
duction; and red, protein not ex- 
pressed. Residue  numbers are pro- 
vided  for sidechains that had  a 
complete or partial  reduction in 
binding.  This  figure was  drawn 
using MIDAS (University of Cal- 
ifornia, San Francisco). 
structure of the molecule.  For comparative purposes,  the 
K10 residue is located within a loop connecting two/3 strands 
A and B. Mutation to K10A did not disrupt the binding by 
WEH1231 or Ramos ceils (Fig. 4 J), nor did it induce gross 
structural changes (Table M). 
This stands in contrast to the $54A mutation, which did 
result in reduction of cell adherence and of the binding of 
nonblocking and blocking antibodies (Table M). Binding by 
blocking antibodies was reduced by 83-93 %, while that of 
nonblocking  antibodies  was  reduced  by  24-53%.  Based 
upon the computer model, $54A is likely buried within/3 
strand E and forms a hydrogen bond with W35 (Figs.  1 and 
5) and thus is essential for the structural integrity of the mol- 
ecule. 
Alanine  substitutions  at  R36,  K46,  T72,  and  E81  also 
resulted in reduced binding  of Ramos cells (Table 1I and 
Figures 4, A,  C, L  and F,, respectively). All four of these 
residues seemed to be structurally important. R36 is next to 
W35, which is hydrogen bonded to $54. The importance of 
this bond is also borne out by mutation of $34, which simi- 
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Mutant 
expression  5.7.1  5.7.4  5.10.8 
mAb Anti-VCAM-I binding to mutants (% of binding to WT) 
Blocking mAb 
5.11.3  35.1.1  59.9.4  59.17.19  M/K-2.7  MVCAM.A429 
WT (MVIdl-4)  +  100  100  100 
293 Mock control  -  0  00  0 
Domain 1 
E8A  +  98  102  101 
K10A  +  100  120  96 
DI7A  +  97  98  98 
E29A  -  0  0  0 
$34A  +  69  70  72 
R36A  +  79  78  80 
T37A  +  61  54  66 
Q38A  -  0  0  0 
IMOA  +  116  110  117 
D40K  +  96  102  97 
N44A  +  102  137  110 
K46A  +  123  106  128 
R48A  +  94  86  93 
E50A  +  84  110  104 
$54A  +  64  52  76 
T57A  +  57  36  58 
E59A  +  80  74  83 
E64A  +  97  105  98 
N65A  +  68  63  63 
E66A  +  103  115  96 
H67A  -  0  0  0 
L70A  -  0  0  0 
T72A  +  72  60  80 
K79A  +  101  95  96 
E81A  +  95  98  96 
R82A  +  107  96  97 
H85A  +  83  69  83 
100  100  100  100  100  100 
0  0  0  0  0  0 
104  104  68  61  123  105 
103  109  100  104  97  103 
92  94  89  84  108  109 
0  0  0  0  ND  ND 
60  65  62  70  51  41 
76  81  76  73  71  42 
60  59  63  66  50  59 
0  0  0  0  ND  ND 
118  113  112  115  102  2 
94  96  78  95  86  0 
106  121  113  98  88  97 
108  126  126  111  89  92 
85  86  82  80  88  97 
98  106  94  93  100  94 
58  47  9  7  12  17 
51  58  53  45  53  53 
77  82  80  82  86  87 
97  104  97  97  101  110 
61  61  39  36  80  77 
106  106  97  91  105  107 
0  0  0  0  ND  ND 
0  0  0  0  ND  ND 
69  70  77  87  73  71 
94  91  104  105  88  101 
92  97  95  86  91  73 
103  91  99  106  103  106 
66  78  62  59  85  64 
larly disrupts antibody binding, but not cell adherence.  The 
R36A mutation had a profound effect on the binding of the 
blocking  anti-VCAM-1  antibody  MVCAM.A429.  K46  is 
predicted to be within B strand D  and partially buried.  E81 
is predicted to be within B strand G adjacent to R82, which 
is partially buried. T72 is on B strand F positioned between 
two buried residues C71 and A73, and might therefore be ex- 
pected to reduce cell binding. 
Of particular  interest  is  the  finding  that  the  degree  of 
reduction in cell binding to the P,36, K46, T72, and E81 mu- 
tants was highly dependent  on the concentration at which 
they were precoated on the microwells.  Higher concentra- 
tions resulted in better binding, while lower concentrations 
resulted in poorer binding,  as compared to equivalent con- 
centrations  of the wild type molecule.  These data suggest 
that while the mutations could disrupt cell adhesive func- 
tion, binding could be augmented by increasing the avidity 
of the interaction or the number of molecules interacting. 
In general, the mutations that affected Ramos cell binding 
also affected the bindingto WEHI 231 cells. However, three 
mutants, K46A, N65A, and ES1A, exhibited reduced bind- 
ing by Ramos cells  while  exhibiting  little  or no effect on 
WEHI 231 cell binding. Representations of N65A and E81A 
are shown in Fig.  4,  G  and H.  The N65A mutation com- 
pletely reduced the binding of Ramos cells, while K46A and 
E81A only partially reduced binding. These results raise the 
possibility that there may be species differences in the recog- 
nition residues  on MVIdl-4. 
Alanlne  substitutions  at  E8,  K10,  D17,  T37,  N44,  R48, 
E50, T57, E64, E66, I(79, R82, and H85 did not alter bind- 
ing by either Ramos or WEH1231 cells (Table ll). There was 
no yield for the three mutations,  E29A, H67A, and LTOA. 
To further test whether a mutant at D40 in the MVIdl-7 
molecule could also exhibit reduction in binding, a panel of 
mutants comprised of mutations D40A, D40E, D40K, and 
D40N  were  prepared:  The  mutants  D40A,  D40K,  and 
D40N, tested at comparable molar concentrations to wild 
type MVIdl-7, reduced binding to background levels.  The 
D40E mutation did not affect binding (Fig. 6). The effect of 
mutation on IM0 was not unique to Ramos or WEH1231 cell 
binding.  The human Jurkat  T  cell  line  binding  to D4OA, 
D40K, and D40N MVIdl-7 mutant molecules was also com- 
pletely inhibited (data not shown). These data are consistent 
with the idea that a change of a  single amino acid residue, 
I)40 in domain 1 of the MVIdl-7 molecule, to a residue with 
either an aliphatic, basic, or amide sidechain is sufficient to 
completely  abrogate  its  binding  by  a4  positive  cells.  An 
acidic sidechain composed of D40 or E40 was sufficient for 
binding. 
Mutation of MVIdl-4 at positions D317A, R324A, Q326A, 
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Figure 6. Rarnos cell binding to mutants of MVIdl-7 or MVIdl-7 
(WT) derived from 293 cell transfections. (A) Mutants captured at 
equivalent concentrations as determined by ELISA analysis as in 
Fig. 4. (B) Rarnos cell binding as determined by fluorescence + 
SD. The binding to 293 mock transfection supernatant is shown as 
a negative control. --a-, WT; --k-, IMOA; --~-, D40E; -/x-, IMOK; 
--o-, D40N; --D-, 293. 
D328A, R336A, E338A, and K341A in the fourth Ig-like do- 
main did not result in reduced binding by Ramos or WEHI 
231  cells (data not shown). These results suggest that the 
fourth domain does not contribute to adhesive function in 
MVIdl-4. 
Specific Amino Acid Residues on Domain 1 
of MVIdl-4 Are Required for the Binding of 
Neutralizing Hamster and Rat Anti-mouse 
VCAM-1 Monoclonal Antibodies 
An analysis of the binding of a panel of adhesion-blocking 
and nonblocking hamster anti-VCAM-1  monoclonal anti- 
bodies was carried out to test whether the same amino acid 
substitutions that perturb cell adherence can result also in al- 
tering antibody binding or whether specific mutations in- 
duced gross structural perturbations in the molecule. Com- 
parative data on the antibodies binding to mutants, relative 
to wild type are summarized in Table HI. 
Alanine substitution at E8  reduced the binding of two 
blocking antibodies, clones 59.9.4  and 59.17.19, to 68 and 
61% of wild-type binding, respectively. There were no mea- 
surable differences in the binding by nonblocking antibodies 
to E8 and wild type. ESA had no impact on the binding of 
WEHI 231 or Ramos cell binding. The D17A mutation also 
slightly reduced blocking antibody binding (to 87  +  4% of 
wild type) without exhibiting any effect on nonblocking anti- 
body binding or cell adhesion. The data suggest that the 
residues E8 and D17 are crucial for binding by blocking anti- 
bodies 59.9.4 and 59.17.19, but not for cell adhesion or other 
anti-VCAM-1  antibodies. 
The mutation R36A reduced the binding of both blocking 
and nonblocking antibodies to a range of 73-81%  of wild- 
type binding (average of 78%).  In the experiments shown 
above, this mutation also resulted in reduced binding by both 
WEHI 231 and Ramos in a mutant dose dependent manner 
(Fig. 4). The results suggest that this mutation may induce 
a subtle change in the conformation of the molecule, thereby 
impacting both antibody binding and adhesion. 
The D40 residue was observed to be key to cell adherence. 
Anti-VCAM-1  antibody-binding  data  suggested  that  the 
D40A and D40K mutations did not result in gross structural 
perturbations (Table HI). Only the binding of one blocking 
anti-VCAM-1  antibody  (MVCAM.A429)  was  completely 
abrogated by the D40A and D40K mutations. The inference 
is that D40 is one residue crucial for cell adherence and bind- 
ing  by  the  blocking  anti-VCAM-1  monoclonal  antibody 
MVCAM.A429. 
Both blocking  and  nonblocking antibodies  showed  re- 
duced binding to mutants $54A and N65A as compared to 
wild type. $54A profoundly reduced the binding of blocking 
antibodies to 8  +  1% (SD) of wild type and the binding of 
nonblocking antibodies to 59 5: 11% of wild type. The $54A 
mutation also inhibited the adherence of  both WEH1231 and 
Ramos. Similarly, the N65A mutant reduced blocking anti- 
bodies to 38 +  2% and nonblocking antibodies to 63 +  3%. 
Both of these mutations seem to more profoundly reduce 
blocking antibody binding than nonblocking antibody bind- 
ing, thus suggesting that these residues influence the struc- 
tural integrity of the molecule, but also contribute signifi- 
cantly to cell adhesive function. 
In summary, alanine substitution of three residues (R36, 
$54,  and N65)  can partially affect the gross  structure of 
mVCAM-1, as  exemplified by their perturbation  of anti- 
VCAM-1 antibody binding. These data are consistent with 
their effect on cell adhesion.  Alanine substitution at E81 
affected the binding of blocking antibody MVCAM.A429 
only, with alteration at E81 causing reduction in binding by 
Ramos cells. Two residues, E8 and D17, seem to be associ- 
ated with the binding of the two blocking anti-VCAM-1 anti- 
bodies, while having no direct influence on cell adhesion. 
D40A, the mutation with the most profound effect on cell 
adhesion, produced a measureable effect on the binding of 
only one blocking antibody, MVCAM.A429. 
Discussion 
We have shown that recombinant soluble mVCAM-1 mole- 
cules, secreted by human 293 cells either as a truncated mol- 
ecule without the transmembrane and cytoplasmic tail do- 
mains, or as an IgG fusion molecule, exhibited ceU adhesive 
functions similar to those previously reported for cell mem- 
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through the lymphocyte t~4/31 receptor. Both murine WEHI 
231 and human Ramos cells binding to immobilized MVdl-7 
or MVIdl-7 could be inhibited by antibodies to either a4 or 
VCAM-1. 
The secreted MVIdl-7 molecule could be truncated to a 
smaller molecular form,  composed of the  first two NH2- 
terminal domains, that retained cell adhesive function com- 
parable to that of MVIdl-7. Pepinsky et al. (31) reported that 
a soluble truncated form of human VCAM-1 derived from 
COS ceils and composed of the first two domains was bound 
by Ramos cells. However, the binding was not inhibited by 
anti-VCAM-1  antibody 4B9. In our investigation, the binding 
of WEHI 231 and Ramos cells to MVIdl-2 was totally in- 
hibited by monoclonal hamster anti-mVCAM-1  antibodies 
59.9.4 and 59.17.19. This minor difference may be explained 
by our use of a different monoclonal anti-VCAM-1  antibody 
or by the study of VCAM-1 derived from murine as opposed 
to human origin. 
By alanine substitution of acidic and basic charged amino 
acid residues in the first domain, the D40 residue was found 
to strongly inhibit binding by both WEHI 231 and Ramos 
cells. A requirement for an acidic sidechain at amino acid res- 
idue 40 was evident with the D40E mutation showing no im- 
pact on cell binding,  while D40A,  D40K,  and D40N in- 
hibited binding.  Alteration of the D40 residue in both the 
MVIdl-4 and the MVIdl-7 version of the soluble mVCAM-1 
molecule led to complete loss of cell binding.  Experimen- 
tally, the loss of adhesive function was not accompanied by 
global molecular structural perturbations, as tested by the 
binding of blocking or nonblocking hamster VCAM-1 anti- 
bodies. The location of D40 on a hydrophilic loop between 
/3 strand C and D of the VCAM-1 molecule suggests that this 
residue might interact directly with ot4/31 receptors. Its loca- 
tion is a region corresponding to the second complementar- 
ity determining region of immunoglobulins. 
In our investigation, the D40A mutation alone in domain 
1 of MVIdl-7 completely inhibited cell adhesiveness. Argu- 
ably, the first domain may make the greatest contribution to 
binding by our recombinant soluble VCAM-1 molecule. In 
our hands, mutation of MVIdl-4 at positions D317A, R324A, 
Q326A, D328A, R336A, E338A, and K341A did not result 
in reduced binding by Ramos or WEH1231 cells, suggesting 
that domain 4  is not required for adhesive function. This 
would appear to be in conflict with the report by Osborn et 
al. (27), who showed that the fourth domain may have cell ad- 
hesive function.  These investigators observed that a  COS 
cell expressing the alternatively spliced six Ig-like domain 
form of human VCAM-1  was bound by Ramos cells. How- 
ever, in their VCAM-1 molecule, the first domain was swapped 
for the fourth domain. Their results and ours are therefore 
complementary. 
A second mutation involving $54A also reduced binding, 
probably by disrupting the hydrogen bonding that normally 
occurs between $54 and W35, as predicted by the computer 
model illustrated in Fig.  6.  The $54A mutation inhibited 
both blocking and nonblocking anti-VCAM-1  antibody bind- 
ing with the effect being greater on blocking antibodies. The 
results suggest that the mutation most likely changed the lo- 
cal conformational structure of the molecule. If so, it fol- 
lows that $54 would influence both cell adhesion and anti- 
body binding. 
There were two distinct patterns seen in the loss of cell 
binding to the mutants.  The mutations D40A,  $54A,  and 
N65A abrogated cell adherence at all concentrations of mu- 
tants tested, whereas the R36A, K46A, and ES1A mutations 
exhibited cell binding at higher precoat concentrations, but 
not at lower mutant precoat concentrations. A possible ex- 
planation for the former observation is that the mutations 
D40 and $54 sufficiently reduced the affinity of the interac- 
tion so that increasing the mutant precoat concentrations did 
not lead to an increase in the avidity of the interaction. On 
the other hand, the R36A mutant had a lower affinity interac- 
tion that was overcome by increasing the precoat concentra- 
tions. These results strongly support the hypothesis that the 
D40 and $54 residues are crucial for maintaining adhesive 
function. These residues are conserved in the mouse, rat, 
and human VCAM-1  molecules. 
The R36 and D40 residues are adjacent to four other al- 
tered residues that exhibited an influence on cell adhesion, 
mutations  K46A,  N65A,  T72A,  and  E81A.  The  K46A, 
N65A, and E81A mutations inhibited partially or completely 
the binding by Ramos cells, while displaying no modification 
of the binding by WEH1231 cells. Possible explanations are 
(a) that homologous interactions between mouse cell and 
mouse protein may be of higher affinity than the heterolo- 
gous ones between human cell and mouse protein; or (b) that 
the structures on MVIdl-4 involved in the binding to Ramos 
cells  may be  slightly different from those for binding  to 
WEHI 231.  Interestingly, these three residues are adjacent 
conformationally to R36 and D40. All are clustered within 
the same region of the molecule and are conserved among 
mouse, rat and human VCAM-1 sequences, suggesting their 
importance for cell adhesive function. 
Only two residues were observed to block antibody associ- 
ation without contributing to cell adhesion.  Alanine sub- 
stitution at two residues, E8 and D17, were able to inhibit 
blocking antibody binding, but induced no effect  on the bind- 
ing by Ramos or WEHI 231 cells. Based on the computer 
model, these two residues are both located in the loop be- 
tween/3 strand A and B (shown at the right hand bottom cor- 
ner of Fig. 5). These residues are not in close proximity to 
the residues influencing cell adhesion. 
Of the residues that did not affect binding either to Ramos 
or WEHI 231  cells, those at positions K10, R48, E64, and 
R82  differ in  sequence between human,  rat,  and  murine 
VCAM-1. This suggests that these positions are not involved 
in species specific interaction even though R48,  E64, and 
R82 are adjacent to residues that did affect binding. 
In summary, by site-directed mutagenesis of a  secreted 
soluble recombinant murine  VCAM-1  molecule,  we have 
identified amino acid residues that influence both cell adhe- 
sion and binding by blocking monoclonal anti-VCAM-1  anti- 
bodies. In particular, the D40A mutation resulted in com- 
plete inhibition of both cell adhesive function and binding by 
blocking  antibody  MVCAM.A429  without  inducing  any 
other structural perturbation. The residues R36, 1340, K46, 
N65, T72, and ES1 are all conformationally close to one an- 
other on a hydrophilic region on the NH2-terminal domain 
1. Although these residues are all located in domain 1, it is 
evident that there is a structural requirement for domains 1 
and 2 to be intact so that cell binding can take place. The 
distribution of these residues on the same face of the mole- 
cule would suggest that the structure on VCAM-1  crucial 
The Journal of Cell Biology, Volume 125,  1994  1404 for adherence to VLA-4 is probably conformationaUy de- 
pendent. 
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